Mesentech Inc.
Mesentech is dedicated to developing innovative drugs that selectively target musculoskeletal tissues, utilizing novel chemistry to deliver payloads such as hormones and anti-cancer agents with high precision. Their technology aims to improve treatment efficacy while minimizing toxicity, with a focus on bone and muscle regeneration, especially for conditions like osteoporosis and muscular dystrophies.
Industries
Nr. of Employees
small (1-50)
Products
Clinical-stage bone-targeted EP4 receptor agonist prodrug
A bone-targeted prodrug conjugate comprising a high-affinity bone-targeting moiety linked to an EP4 receptor agonist payload; designed to bind bone, minimize systemic exposure, and locally release active agonist over days.
Bone-selective oncology small-molecule conjugate (preclinical)
A small-molecule anti-cancer payload formulated as a bone-targeted conjugate designed to selectively distribute to bone tissue for localized oncology applications.
Clinical-stage bone-targeted EP4 receptor agonist prodrug
A bone-targeted prodrug conjugate comprising a high-affinity bone-targeting moiety linked to an EP4 receptor agonist payload; designed to bind bone, minimize systemic exposure, and locally release active agonist over days.
Bone-selective oncology small-molecule conjugate (preclinical)
A small-molecule anti-cancer payload formulated as a bone-targeted conjugate designed to selectively distribute to bone tissue for localized oncology applications.
Services
Collaborative preclinical research and licensing agreements
Partnership-based collaborations for translational evaluation, preclinical testing and IP licensing of bone-targeting conjugates; engagement with accelerators and external research platforms.
Collaborative preclinical research and licensing agreements
Partnership-based collaborations for translational evaluation, preclinical testing and IP licensing of bone-targeting conjugates; engagement with accelerators and external research platforms.
Expertise Areas
- Bone-targeted drug delivery
- Prodrug and linker chemistry
- Preclinical pharmacokinetics and biodistribution
- Bone regeneration and biomaterials
Key Technologies
- Bisphosphonate-mediated bone targeting
- Prodrug conjugation and linker chemistry
- Radiolabeling for pharmacokinetics and biodistribution
- Microcomputed tomography (microCT)